Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent guidance on Orexigen’s Contrave could provide clues about how the agency is leaning on drugs in the highly safety conscious obesity category. New analysis of SCOUT data for Abbott’s withdrawn Meridia (sibutramine) could crop up in the discussion, former panelist says.
You may also be interested in...
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.
Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors
Arena Pharmaceuticals gets new May 10 advisory committee review for its obesity therapy lorcaserin; execs say the recent positive review for competing Qnexa bodes well, and that this time around the risk/benefit profile for lorcaserin is much stronger.
Financings Of The Fortnight Puts On The Weight
Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.